AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02)
AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02)
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control.
The study is seeking for participants who:
All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV) infusion (give directly into a vein). In addition, half of the participants will also receive Sigvotatug Vedotin once every 2 weeks as an IV infusion in addition to receiving pembrolizumab.
Participants may receive pembrolizumab for up to about two years. Those participants taking Sigvotatug Vedotin can continue until their NSCLC is no longer responding. The study team will monitorsee how each participant is doing with the study treatment during regular visits at the clinic.
Inclusion Criteria:
Participants must meet the following criteria:
Tumor has PD-L1 expression in ≥50% of tumor cells (TPS ≥50%) as determined by local testing
Measurable disease based on RECIST v1.1 per investigator.
Resolution of acute effects of any prior therapy to either baseline severity or NCI CTCAE Grade 1 or less (except for AEs not constituting a safety risk in the investigator's judgment), unless otherwise excluded.
Exclusion Criteria:
Life expectancy of <3 months in the opinion of the investigator.
Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or make the participant inappropriate for the study.
Participants with any history of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.
Known or suspected hypersensitivity, intolerance, or contraindication to any excipient contained in the drug formulation of sigvotatug vedotin or pembrolizumab.
Participants with any of the following respiratory conditions:
Known active CNS lesions are excluded. Participants with definitively treated brain metastases (surgery and/or radiotherapy) may be eligible. Clinically inactive brain metastases of longest diameter <0.5 cm are permitted.
Major surgery (defined as a surgery requiring inpatient hospitalization of at least 48 hours) within 21 days or minor surgery within 7 days prior to first dose of study intervention.
Receipt of a live vaccine within 30 days prior to first dose of study intervention.
Pre-existing peripheral neuropathy Grade ≥2 per NCI CTCAE v5.0.
Uncontrolled diabetes mellitus, defined as HbA1c ≥8.0% or HbA1c between 7.0% and 8.0% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained.
Prior immune-related AE that led to anti-PD-(L)1 treatment discontinuation, required a high-dose steroid taper (≥0.5 mg/kg prednisone or equivalent per day) for >2 weeks, or required treatment with systemic immunosuppressive therapy.
History of autoimmune disease that has required systemic treatment in the past 2 years
Participants with prior solid organ or bone marrow transplantation.
Currently receiving a high-dose steroid (>10 mg prednisone or equivalent per day) or other immune suppressant or has a condition requiring a chronic high-dose steroid or immune suppressant.
Prior and concomitant therapy:
Any prior treatment with MMAE-derived drugs or IB6 targeting agents.
Prior systemic therapy, including anti-PD-(L)1 therapy, for locally advanced, unresectable, or metastatic NSCLC.
Prior radiotherapy to the lung within 6 months of first dose of study intervention, referencing the last date radiotherapy was received.
Chemotherapy, biologics, and/or other antitumor treatment with immunotherapy not specifically prohibited that is completed less than 4 weeks prior to first dose of study intervention, or 2 weeks for palliative radiotherapy.
Any prior therapy with an immune-oncology agent directed to a stimulatory or co-inhibitory T-cell receptor
History of or current ongoing infection, including participants positive for active HIV, HBV, or HCV.
Severe uncontrolled cardiac or cerebrovascular condition within the previous 6 months
ClinicalTrials.gov_Inquiries@pfizer.com1-800-718-1021
Fullerton, California 92835, United States
Fullerton, California 92835, United States
Grand Junction, Colorado 81501, United States
Grand Junction, Colorado 81501, United States
Washington D.C., District of Columbia 20422, United States
Scarborough, Maine 04074, United States
Grand Rapids, Michigan 49503, United States
Grand Rapids, Michigan 49503, United States
Grand Rapids, Michigan 49503, United States
Saint Louis Park, Minnesota 55426, United States
Woodbury, Minnesota 55125, United States
Fremont, Nebraska 68025, United States
Grand Island, Nebraska 68803, United States
Grand Island, Nebraska 68803, United States
Omaha, Nebraska 68114, United States
Omaha, Nebraska 68124, United States
Omaha, Nebraska 68130, United States
Greenville, North Carolina 27834, United States
Avon, Ohio 44011, United States
Mentor, Ohio 44060, United States
Conroe, Texas 77384, United States
Houston, Texas 77030, United States
Houston, Texas 77030, United States
Houston, Texas 77030, United States
Houston, Texas 77054, United States
Houston, Texas 77079, United States
League City, Texas 77573, United States
Sugar Land, Texas 77478, United States
Olympia, Washington 98502, United States
Olympia, Washington 98506, United States
Berazategui, Buenos Aires B1884BBF, Argentina
Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ABP, Argentina
Florida, Buenos Aires B1602DQD, Argentina
Buenos Aires, Cdad. Autónoma de Buenos Aires C 1113, Argentina
Liège, 4000, Belgium
Fortaleza, Ceará 60430235, Brazil
Vitória, Espírito Santo 29043-260, Brazil
Salvador, Estado de Bahia 41253-190, Brazil
Brasília, Federal District 70390-150, Brazil
Recife, Pernambuco 52010-902, Brazil
Ijuí, Rio Grande do Sul 98700-000, Brazil
Bragança Paulista, São Paulo 12916-542, Brazil
Ribeirão Preto, São Paulo 14051-140, Brazil
São José do Rio Preto, São Paulo 15090000, Brazil
Sofia, 1407, Bulgaria
Sofia, 1756, Bulgaria
Beijing, Beijing Municipality 101149, China
Luoyang, Henan 471003, China
Hangzhou, Zhejiang 310016, China
Wenzhou, Zhejiang 325000, China
Liberec1, 460 01, Czechia
Quimper, Brittany Region 1757 - 29107, France
Rennes, Ille-et-vilaine 35033, France
Montpellier, Languedoc-roussillon 34070, France
Saint-Herblain, Loire-atlantique 44800, France
Toulon, Provence-Alpes-Côte d'Azur Region 83100, France
Koblenz, Rhineland-Palatinate 56068, Germany
New Delhi, National Capital Territory of Delhi 110005, India
Meldola, Emilia-Romagna 47014, Italy
Pesaro (PU), Pesaro AND Urbino 61121, Italy
Otashi, Gunma 373-8550, Japan
Bunkyo-ku, Tokyo 113-8603, Japan
Chuo-ku, Tokyo 104-0045, Japan
Koto, Tokyo 135-8550, Japan
Meguro-Ku, Tokyo 152-8902, Japan
Guadalajara, Jalisco 44340, Mexico
Breda, North Brabant 4818 CK, Netherlands
Warsaw, Masovian Voivodeship 02-781, Poland
Gliwice, 44-102, Poland
Poznan, 60-569, Poland
Bucharest, Bucharest 022338, Romania
Florești, Cluj 407280, Romania
Bratislava, Bratislava Region 821 01, Slovakia
Hwasun-gun, Jeonranamdo 58128, South Korea
Suwon, Kyǒnggi-do 16247, South Korea
Haeundae-gu, Pusan-kwangyǒkshi 48108, South Korea
Seoul, Seoul-teukbyeolsi [seoul] 03722, South Korea
Deagu, Taegu-kwangyǒkshi 41404, South Korea
A Coruña, A Coruña [LA Coruña] 15006, Spain
L'Hospitalet de Llobregat, Catalunya [cataluña] 08908, Spain
Barcelona, 08035, Spain
Barcelona, 08035, Spain
Las Palmas de Gran Canaria, 35016, Spain
Taipei City, Taipei 106, Taiwan
Kaohsiung City, 807, Taiwan
Istanbul, İ̇stanbul 34722, Turkey (Türkiye)
Ankara, Turkey 06230, Turkey (Türkiye)
Ankara, 06560, Turkey (Türkiye)
İstanbul - Fatih, 34098, Turkey (Türkiye)
Southampton, Hampshire SO16 6YD, United Kingdom